Quality Of Life Assessment And Clinical Observation On Treatment Of Nonalcoholic Fatty Liver Disease With Shugan-Xiaozhi Decoction

ObjectiveTo assess the quality of life and observe the clinical effects in treatment of patients with non-alcoholic fatty liver disease with Shugan-Xiaozhi Decoction.In order to comprehensively and objectively evaluate the comprehensive impact of Shugan-Xiaozhi Decoction on treating non-alcoholic fatty liver disease.MethodsIn strict accordance with the inclusion and exclusion criteria,98 patients with non-alcoholic fatty liver disease were enrolled,and49 patients were randomly divided into the experimental group and the control group.The control group was given lifestyle guidance,a diet and exercise execution plans were given.The experimental group also followed the lifestyle guidance,at the same time orally took with Shugan-Xiaozhi Decoction.The treatment course was 12 weeks.The chronic liver disease questionnaire-non-alcoholic fatty liver disease version(CLDQ NAFLD-NASH)scale was used to assess the changes in quality of life before and after treatment in both groups,and the body mass index(BMI),CAP value,ALT,AST,GGT,TC,TG,FPG,NFS score,TCM main symptom score before and after treatment were observed in both groups to evaluate the changes and differences.After collecting and sorting data,SPSS 20.0 was used for statistical analysis to evaluate the quality of life and efficacy of Shugan-Xiaozhi Decoction in treating patients with non-alcoholic fatty liver disease.Results1.There was no significant difference in gender,age,and course of disease between the two groups at baseline.From this study,nonalcoholic fatty liver disease mostly happened in men than women,mainly young and middle-aged people,and the course is long.2.The "Chronic Liver Disease Questionnaire-NonAlcoholic Fatty Liver Disease Edition(CLDQ NAFLD/NASH)" was used to assess the quality of life of patients with non-alcoholic fatty liver disease.After treatment,the abdominal symptoms(AS),fatigue(FA),systemic symptoms(SS),and activity(AC),emotional(EF),and worry(WO)of the experimental group were significantly improved(all P<0.01).The control group showed significant improvement in abdominal symptoms(AS),fatigue(FA),activity(AC),and emotional(EF)(P<0.05,P<0.01,P<0.05,P<0.05),without significant improvement in systemic symptoms(SS)and worry(WO)(all P>0.05).In abdominal symptoms(AS),fatigue(FA),systemic symptoms(SS),activity(AC),emotion(EF),and worry(WO)experimental group was better than the control group(P<0.01,P<0.01,P<0.01,P<0.05,P<0.05,P<0.05).3.On the reduction of BMI,after treatment,the BMI in both groups was significantly reduced(P<0.01),there was no significant difference between the two groups(P>0.05),but the difference between the experimental group before and after treatment was significantly lower than the control group(P<0.01).4.In improving the CAP value,the total effective rate of the experimental group was 91.84%,and the control group was 59.18%.The experimental group was significantly better than the control group(P<0.05).In improving the LSM value,after treatment,neither groups shew difference(P>0.05).5.In improving liver function,after treatment,both groups can significantly reduce the levels of ALT,AST,and GGT(P<0.01).There is no significant difference between the two groups(P>0.05),but the difference before and after treatment in the experimental group Larger than the control group(P<0.05).6.In improving blood lipids,after treatment,the experimental group can significantly reduce the levels of TG,TC,and LDL-C(P<0.01),and the control group can significantly reduce the levels of TG and TC(P<0.01),but cannot significantly reduce LDL-C.Level(P>0.05).After treatment there is significant difference between the two groups in TC(P<0.05)but no significant difference in TG and LDL-C(P>0.05).The difference before and after treatment in the experimental group was significantly greater than that in the control group(P<0.05).7.In improving FPG level,after treatment,both groups can significantly reduce FPG level(P<0.01),the experimental group is better than the control group(P<0.01),and the difference in the experimental group is greater than the control group(P<0.01).8.Evaluating the efficacy by the traditional Chinese medicine main symptoms quantity,the total efficacy rate in the experimental group was 85.71%,rather the control group was 63.27%.The experimental group was significantly better than the control group(P<0.05).Conclusions9.Given lifestyle intervention as a foundation treatment,combine Shugan-Xiaozhi Decoction can improve the quality of life of patients with non-alcoholic fatty liver disease and the clinical efficacy,including biochemical indicators and medical imaging.Therefore,the traditional Chinese medicine method of eliminating fat,clearing heat and soothing liver has an obvious effect on regulating patients’metabolic state and liver fat deposition,which are worthy of clinical promotion.